Top Private Equity News, Member Posts, Managed Futures Daily Indices and more!

3yrs ago Private Equity privateequitywire Views: 377

Merck to acquire Pappas Capital portfolio company VelosBio in USD2.75bn deal

Submitted 05/11/2020 - 10:54am

Pappas Capital's portfolio company, VelosBio Inc (VelosBio), is to be acquired by a subsidiary of Merck for USD2.75 billion in cash, subject to customary adjustments. 

The exit is amongst Pappas Capital’s most successful in its 25-plus-year history.

 
VelosBio is a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Pappas Capital first invested in VelosBio in 2018 as part of the Company’s USD58 million Series A financing. Encouraged by the strong potential of VelosBio’s novel therapies for difficult-to-treat cancers, Pappas Capital subsequently participated in the Company’s USD137 million Series B financing in July 2020.
 
Pappas Managing Partner Kyle Rasbach, PhD, PharmD. has served as a VelosBio Board Observer, providing hands-on support and guidance to the Company’s leadership team and Board of Directors on the development of VelosBio’s investigational candidate (VLS-101). VLS-101 is an antibody-drug conjugate (ADC) targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with haematologic malignancies and solid tumours, respectively.
 
Dr Rasbach says: “At Pappas, our focus has long been on identifying and executing on investment opportunities in innovative life science companies and partnering with exceptional teams to bring these technologies to market. VelosBio serves as an ideal example of our strategy at work, and we are thrilled to watch the Company embark on its next phase of growth as part of Merck.”
 
“This acquisition is a transformative event that will propel the advancement of VLS-101 as a potential new cancer treatment, and we are humbled to have worked closely with the VelosBio team to achieve this milestone. We look forward to continuing to build upon our investment track record by sourcing new opportunities that seek to not only provide superior results to our investors, but just as importantly, improve the lives of patients.”

Tags Deals & Transactions Acquisitions Exits

Today's Private Equity Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.